rFVIII
:Haemostatic agent
:Phase 3
Novo Nordisk is developing a 3rd generation recombinant factor VIII product for the treatment of haemophilia A.
- Company announcements
- Financial statement for the first quarter of 2001 (08 May 2001)
- Read more company announcements
- Press releases
- No press releases matching the search criteria
- Scientific abstracts
- Haemophilia (2009)
- Haemophilia (2009)
- Journal of Thrombosis and Haemostasis (2008)
- Read more scientific abstracts
